U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07937254) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)' on Nov. 08.

Brief Summary: This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).

Study Start Date: Oct. 19

Study Type: INTERVENTIONAL

Condition: Lipid Metabolism Disorders Healthy Volunteers - Male and Female Hyperlipoproteinemia(a)

Intervention: DRUG: JAR-2203

JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels ar...